NCT05056896 is a EARLY_PHASE1 clinical trial of Aspirin in Colorectal Cancer, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT05056896?

NCT05056896 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT05056896?

Interventions in NCT05056896: Aspirin, Placebo.

What condition does NCT05056896 study?

NCT05056896 studies Colorectal Cancer.

Is NCT05056896 still recruiting?

NCT05056896 is currently active, enrolled. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT05056896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

Active, enrolled EARLY_PHASE1 Last updated 16 January 2026

What this trial tests

EARLY_PHASE1 trial testing Aspirin in Colorectal Cancer in 161 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 June 2022

Primary endpoint
27 November 2024

31 December 2026

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	161
Start date	3 June 2022
Primary completion	27 November 2024
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Aspirin — full drug profile →
Placebo

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: * Low Dose Aspirin

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017
Multidimensional decoding of colorectal cancer heterogeneity: Artificial intelligence-enabled precision exploration of single-cell and spatial transcriptomics.
Luan WY, Zhao Q, Zhang Z, Xu ZX, et al · · 2025 · cited 1× · PMID 41114099 · DOI 10.4251/wjgo.v17.i10.110661

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

NCT07525635 — Aspirin Dosing in Pregnancy · EARLY_PHASE1 · not yet recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
NCT07373756 — Randomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk · Phase 4 · not yet recruiting
NCT07180472 — Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol · Phase 4 · not yet recruiting
NCT06638151 — Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) · Phase 2 · recruiting

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05056896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05056896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing